ea0090p666 | Endocrine-related Cancer | ECE2023
Ganawa Shawg
, Mashamba Chiedza
, Ilyas Waqas
, Higham Claire
, Cooksley Tim
, Hoong Ho Jan
, Adam Safwaan
, Dhage Shaishav
Introduction: Immunotherapy has transformed the outcomes of various cancers. Monoclonal antibodies against cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD1) and its ligand, PDL1 target mainly T cells, unleashing the immune system against tumour cells. Immune checkpoint inhibitor therapy results in a variety of immune related adverse events, including various endocrinopathies. Thyroid disorders, pituitary disorders are relatively more common compared to pr...